Opinion
Video
Barriers to Accessing New Anti-Diabetes Medications
Author(s):
Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.
EP: 1.Defining Resistant Diabetes
EP: 2.Differentiating Medication Non-Adherence From Underlying Comorbidities
Now Viewing
EP: 3.Barriers to Accessing New Anti-Diabetes Medications
EP: 4.Suspecting Hypercortisolism in Patients With Resistant Diabetes
EP: 5.Testing for Hypercortisolism
EP: 6.Patient Subgroups With a Higher Prevalence of Hypercortisolism
EP: 7.Evolving Perception of Autonomous Adrenal Hypercortisolism
EP: 8.Pathophysiology of Hypercortisolism
EP: 9.Need to Address Underlying Hypercortisolism
EP: 10.Approaching Treatment in Hypercortisolism
EP: 11.Choosing Between Medical and Surgical Options for Hypercortisolism
EP: 12.Long-Term Outcomes for Patients Treated for Hypercortisolism
Related Videos
Related Content
